<DOC>
	<DOCNO>NCT00054457</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine docetaxel capecitabine treat patient metastatic cancer stomach gastroesophageal junction .</brief_summary>
	<brief_title>Docetaxel Capecitabine Treating Patients With Metastatic Cancer Stomach Gastroesophageal Junction</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective tumor response rate patient metastatic gastric gastroesophageal junction adenocarcinoma treat docetaxel capecitabine . - Determine time progression patient treat regimen . - Determine overall survival patient treat regimen . - Determine toxic effect regimen patient . - Determine whether interleukin-1 polymorphism present among patient weight loss v weight loss , relationship poor prognosis . - Assess quality life swallow uniscale chemotherapy patient . OUTLINE : Patients receive docetaxel IV 1 hour day 1 oral capecitabine twice daily day 1-14 . Courses repeat every 21 day 2 year absence disease progression unacceptable toxicity . Quality life assess baseline , tumor measurement , end treatment . Patients follow every 3 month disease progression every 6 month 3 year registration .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma stomach gastroesophageal junction Deemed unresectable candidate potentially curative treatment ( e.g. , surgical resection combine modality therapy ) At least 4 week since prior abdominal exploration resection ( 3 week without resection ) No conventional form therapy available reasonable chance cure significant palliation Measurable disease* The following consider measurable disease : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging Cystic lesion NOTE : *Patients lesion measure â‰¥ 1 cm &lt; 2 cm must use spiral CT scan tumor assessment . No untreated treat symptomatic CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great upper limit normal ( ULN ) AST great 2.5 time ULN alkaline phosphatase less ULN OR Alkaline phosphatase great 4 time ULN AST less ULN Renal Creatinine normal Creatinine clearance least 60 mL/min Cardiovascular No New York Heart Association class III IV heart disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Ability swallow capecitabine No prior anaphylactic reaction taxane No prior severe reaction fluoropyrimidine No prior poor tolerance capecitabine No known sensitivity poor tolerance fluorouracil No known dihydropyrimidine dehydrogenase deficiency No uncontrolled infection No uncontrolled seizure disorder No chronic debilitate disease No peripheral neuropathy etiology great grade 1 No diabetes mellitus No malignancy within past 5 year except adequately treat basal cell squamous cell carcinoma adequately treat noninvasive carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy biologic therapy recurrent metastatic disease No concurrent biologic therapy Chemotherapy No prior chemotherapy recurrent metastatic disease except follow : Adjuvant chemotherapy complete resection original tumor Neoadjuvant chemotherapy follow surgical resection original tumor No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy except follow : Adjuvant radiotherapy complete resection original tumor Neoadjuvant radiotherapy follow surgical resection original tumor No prior radiotherapy 25 % bone marrow More 4 week since prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics No prior organ allograft Other No concurrent brivudine sorivudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
</DOC>